Robert Errol Jones
Physician in Park City, UT
License number
Utah 328208-1205
Issued Date
Sep 27, 1996
Expiration Date
Jan 31, 2018
Category
Physician
Type
Physician & Surgeon
Address
Address
Park City, UT
Personal information
See more information about Robert Errol Jones at radaris.comName
Address
Phone
502 Southwest St, Logan, UT 84321
Professional information
See more information about Robert Errol Jones at trustoria.com
Beta-Superfamily Conotoxins
Beta-Superfamily Conotoxins
US Patent:
2003017, Sep 11, 2003
Filed:
Jan 29, 2002
Appl. No.:
10/058053
Inventors:
Robert Jones - Park City UT, US
Baldomero Olivera - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K038/17, A61K038/43, C07K014/435
US Classification:
424/094100, 514/012000, 530/324000
Abstract:
The present invention is directed to -superfamily conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors. The invention is further directed to nucleic acid sequences encoding the -superfamily conotoxin peptides and encoding -superfamily conotoxin propeptides, as well as the -superfamily conotoxin propeptides.
Kappa-A Conopeptides And Uses Therefor
Kappa-A Conopeptides And Uses Therefor
US Patent:
2006001, Jan 19, 2006
Filed:
Jul 6, 2005
Appl. No.:
11/174996
Inventors:
Richard Layer - Sandy UT, US
Karen Pemberton - Guilford CT, US
Robert Jones - Park City UT, US
James Garrett - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
David Hillyard - Salt Lake City UT, US
Michelle Grilley - Logan UT, US
Maren Watkins - Salt Lake City UT, US
Ameurfina Santos - Quezon City, PH
Glenn Zafaralla - Livonia MI, US
A. Craig - Solana Beach CA, US
Karen Pemberton - Guilford CT, US
Robert Jones - Park City UT, US
James Garrett - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
David Hillyard - Salt Lake City UT, US
Michelle Grilley - Logan UT, US
Maren Watkins - Salt Lake City UT, US
Ameurfina Santos - Quezon City, PH
Glenn Zafaralla - Livonia MI, US
A. Craig - Solana Beach CA, US
Assignee:
Cognetix, Inc. - Salt Lake City UT
University of Utah Research Foundation - Salt Lake City UT
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 38/16, C07K 14/435
US Classification:
514008000, 530322000, 530324000
Abstract:
The present invention is directed to kappaA (κA) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The κA conopeptides include unglycosylated and O-glycosylated peptides.
Kappa-A Conopeptides And Uses Thereof
Kappa-A Conopeptides And Uses Thereof
US Patent:
2003018, Sep 25, 2003
Filed:
May 7, 2002
Appl. No.:
10/139272
Inventors:
Richard Layer - Sandy UT, US
Karen Pemberton - Guilford CT, US
Robert Jones - Park City UT, US
James Garrett - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
David Hillyard - Salt Lake City UT, US
Michelle Grilley - Seattle WA, US
Maren Watkins - Salt Lake City UT, US
Ameurfina Santos - Quezon City, PH
Glenn Zafaralla - Livonia MI, US
A. Craig - Solana Beach CA, US
Karen Pemberton - Guilford CT, US
Robert Jones - Park City UT, US
James Garrett - Salt Lake City UT, US
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
David Hillyard - Salt Lake City UT, US
Michelle Grilley - Seattle WA, US
Maren Watkins - Salt Lake City UT, US
Ameurfina Santos - Quezon City, PH
Glenn Zafaralla - Livonia MI, US
A. Craig - Solana Beach CA, US
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
The present invention is directed to kappaA ( A) conopeptides and the use of these peptides for blocking the flow of potassium ions through voltage-gated potassium channels. The A conopeptides include unglycosylated and O-glycosylated peptides.
Cone Snail Peptides
Cone Snail Peptides
US Patent:
2003010, Jun 12, 2003
Filed:
Feb 11, 2002
Appl. No.:
10/072602
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Lourdes Cruz - Manila, PH
Michelle Grilley - Logan UT, US
Robert Schoenfeld - Sacramento CA, US
Craig Walker - Salt Lake City UT, US
Reshma Shetty - Salt Lake City UT, US
Robert Jones - Park City UT, US
J. McIntosh - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Lourdes Cruz - Manila, PH
Michelle Grilley - Logan UT, US
Robert Schoenfeld - Sacramento CA, US
Craig Walker - Salt Lake City UT, US
Reshma Shetty - Salt Lake City UT, US
Robert Jones - Park City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K038/00, C07K005/00, C07K016/00, C07K007/00, C07K017/00, C07H021/04, C12N001/20, C12N015/00, C12N015/09, C12N015/63, C12N015/70, C12N015/74, C12N005/00, C12N005/02
US Classification:
530/324000, 514/012000, 536/023500, 435/320100, 435/252300, 435/325000
Abstract:
The present invention is directed to conotoxin peptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated ion channels, voltage-gated ligand channels and/or receptors. The invention is further directed to nucleic acid sequences encoding the conotoxin peptides and encoding propeptides, as well as the propeptides.